Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2023-04-26 Regulatory Filings
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
POST-EFFECTIVE AMENDMENT NO. 4 TO FORM S-1
Regulatory Filings
2023-04-26 English
POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 2 to a Registration Statement on Form S-1 filed with the SEC by ABVC Biopharma, Inc. It is a registration statement amendment related to securities offerings, specifically concerning the registration of shares underlying previously issued warrants. The document includes a preliminary prospectus and detailed information about the offering, risk factors, management discussion, and other disclosures typical of a registration statement. Form S-1 and its amendments are filings related to securities registration and capital raising activities, which fall under capital/financing updates rather than annual reports, earnings releases, or other categories. The document is not an annual report, audit report, earnings release, or any other report type but a regulatory filing related to capital raising. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a substantive filing, not a brief announcement or certification, supporting a high confidence score.
2023-04-26 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated April 24, 2023, for ABVC BioPharma, Inc. It is a preliminary prospectus related to the resale of shares by selling stockholders. The text includes detailed information about the offering, selling stockholders, risk factors, management discussion and analysis, business overview, and other sections typical of a registration statement for securities offering. This is not an annual report, earnings release, or any other financial report but a capital markets filing related to securities registration and offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement or certification, so it is not RPA or RNS. Confidence is high due to clear identification of Form S-1 and registration statement context.
2023-04-24 English
CURRENT REPORT
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 24, 2023, reporting the results of the company's 2023 annual meeting of shareholders. It details voting outcomes on director elections, appointment of the independent auditor, and authorization related to Nasdaq listing rules. The content focuses on the submission of matters to a vote of security holders and the official voting results. There is no detailed financial data or comprehensive report content, but rather a disclosure of voting results from the annual meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is about 5,148 characters, which is consistent with a voting results announcement rather than a full annual report or other detailed filings.
2023-04-24 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2023-04-14 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Preliminary Proxy Statement (Schedule 14A) filed with the SEC for the 2023 Annual Meeting of Shareholders of ABVC BioPharma, Inc. It includes detailed information about the meeting date, proposals to be voted on (such as election of directors, ratification of auditor, and approval of stock issuance), voting instructions, and proxy solicitation details. The document is not the actual Annual Report, nor is it a voting results announcement or a report publication announcement. It is a proxy solicitation document intended to inform shareholders and solicit their votes for the upcoming meeting. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is a full proxy statement, not a brief announcement or certification.
2023-04-03 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.